tryc_app_icon_167x167.png
Fundable for Life, Inc. Partners with FMS Franchise to Provide its Clients TV and Digital Print Media Along with Funding Options
December 13, 2023 08:00 ET | Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.
WUGEN-Logo-White-Background-FIN.jpg
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting
December 11, 2023 15:00 ET | Wugen
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at ASH 2023
tryc_app_icon_1024x1024.png
Fundable for Life, Inc. Partners with Top Doctor Magazine to Provide its Members TV and Print Media Along with Funding Options
December 11, 2023 13:05 ET | Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.
gallanttherapeutics-bw (3).png
Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis
December 06, 2023 08:19 ET | Gallant Therapeutics
Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis
redish.jpg
Re:Dish Secures Spot on Inc.'s 2023 Best in Business List By Eliminating Nearly 2 Million Single-Use Packaging Items in First Full Year of Operation
December 05, 2023 10:48 ET | Re:Dish Co.
Re:Dish Secures Spot on Inc.'s 2023 Best in Business List By Eliminating Nearly 2 Million Single-Use Packaging Items in First Full Year of Operation
Healis Therapeutics selected to speak on opening day of 2024 Biotech Showcase in San Francisco
December 05, 2023 08:00 ET | Healis Therapeutics
Healis Co-Founders Sebastian De Beurs and Dr. Eric Finzi will be presenting on the company's neurotherapeutics pipeline and clinical development.
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
November 27, 2023 09:00 ET | Biodexa Pharmaceuticals PLC
Cardiff , Nov. 27, 2023 (GLOBE NEWSWIRE) -- 27 November 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to...
SHMNLogo.jpg
SOHM Announces New CDMO GMP Manufacturing Facility in Carlsbad, California
November 21, 2023 09:30 ET | SOHM, Inc.
CHINO HILLS, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs...
t-therapeutics_logo.png
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment
November 15, 2023 02:00 ET | T-Therapeutics
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis...
CARGO Therapeutics Announces Pricing of Initial Public Offering
November 09, 2023 20:07 ET | Cargo Therapeutics, Inc.
CARGO Therapeutics Announce Pricing of IPO